Press Releases

OncoSec to Host Third Quarter Financial Conference Call on June 1, 2017

SAN DIEGO, May 11, 2017 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that the Company will host its fiscal third quarter 2017 financial results conference call on Thursday, June 1 at 1:15 PM PT/4:15 PM ET.

To access the audio broadcast, please dial (877) 731- 1960 and enter the conference ID number: 20167930. An archived version of the presentation will be available for 90 days on the "Investors" section of OncoSec's website:

About OncoSec Medical Incorporated
OncoSec is a biotechnology company developing DNA-based intratumoral immunotherapies with an investigational technology, ImmunoPulse®, for the treatment of cancer.  ImmunoPulse® is designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as IL-12. In Phase I and II clinical trials, ImmunoPulse® IL-12 has demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various solid tumors as well as the potential to initiate a systemic immune response. OncoSec's lead program, ImmunoPulse® IL-12, is currently in clinical development for several indications, including metastatic melanoma, and triple-negative breast cancer. The program's current focus is on the significant unmet medical need in patients with melanoma who are refractory or non-responsive to anti-PD-1/PD-L1 therapies. In addition to ImmunoPulse® IL-12, the Company is also identifying and developing new immune-targeting agents for use with the ImmunoPulse® platform. For more information, please visit

Investor Relations 
OncoSec Medical Incorporated

Media Relations 
OncoSec Medical Incorporated

OncoSec Medical, Inc. Logo. Please visit for more information. (PRNewsFoto/OncoSec Medical, Inc.) (PRNewsfoto/OncoSec Medical Incorporated)


To view the original version on PR Newswire, visit:

SOURCE OncoSec Medical Incorporated